Biobijou

At a glance

Biobijou filed 20 disclosures in the last 12 months, including 2 buyback, 1 5% holder and 1 issuance. The most recent key filing was on Oct 2.

Revenue for 2025 was ₩28.5B, down 3.9% on 2024. Operating margin was 14.8% against 31.1% a year earlier. Debt was 3% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩17.9B and operating profit of ₩5.3B.

The 2025 annual report lists 51 employees with an average tenure of 1.5 years and average pay of ₩49.7M, #1462 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩113M each on average. It paid ₩100 per common share in cash dividends. (주)청담글로벌 and related parties held 52.84% at year end.

From the 2025 annual report

Staff: 51 (22 men, 29 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩2.1B. Directors and auditors: 5, paid ₩563M in total.

Dividends (common shares)

Largest shareholder

(주)청담글로벌 holds 50.85%; with 1 related party the group holds 52.84% of common shares at year end (from 66.50% at the start of the year).

Auditor: 대주회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary